

May 10, 2019



Khiron Mails and Files Circular Relating to its Annual General and Special Meeting of Shareholders

- *Annual General and Special Meeting of Shareholders scheduled for May 31, 2019 at 11 a.m. (Toronto time).*
- *Proxy voting deadline is May 29, 2019 at 11 a.m. (Toronto time).*
- *Board of Directors recommends that Shareholders vote FOR all resolutions.*

TORONTO, May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("**Khiron**" or the "**Company**") (TSXV: [KHRN](#)), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "**Meeting Materials**") to Khiron's shareholders ("**Shareholders**") in connection with the annual general and special meeting of Shareholders (the "**Meeting**"). The Meeting Materials have also been filed with regulators and electronic copies are available on SEDAR under its profile at www.sedar.com.

The Meeting is scheduled to be held on Friday, May 31, 2019 at 11:00 a.m. (Toronto time) at 1600-100 King St. W., Toronto, ON M5X 1G5.

Cast Your Vote in Support

Shareholders are encouraged to read the Meeting Materials in detail and cast their vote in favour of all resolutions prior to the proxy voting cut-off on May 29, 2019 at 11 a.m. (Toronto time). Voting is easy. Shareholders may vote online, by telephone or other methods described in the form of proxy or voting instruction form that shareholders will receive in the mail.

The Board of Directors of Khiron UNANIMOUSLY recommends that Shareholders Vote FOR all proposed resolutions.

Shareholder Questions

Shareholders who have questions or require assistance with voting may contact Khiron's Proxy Solicitation Agent:

Laurel Hill Advisory Group

North America toll-free: 1-877-452-7184

International: 416-304-0211

Email: assistance@laurelhill.com

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at www.khiron.ca.

To be added to the distribution list, please email khiron@kcsa.com with "Khiron" in the subject line.

Cautionary Notes

Forward-Looking Statements

This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking are based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market and economic risks, uncertainties and contingencies that may cause actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Phil Carlson; KCSA Strategic Communications T. (212)-896-1233 E: khiron@kcsa.com; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca